TOTAL: $2,299.4M | ||||
Company (Symbol)# |
Type Of Financing |
Number Of Shares, Units Or Warrants (M) |
Amount Raised (M) |
Investors; Placement Agents; Details (Date)@ |
Adeona Pharmaceuticals Inc. (AMEX:AEN) |
Equity financing |
1 .2S |
$1 |
Adeona raised $1M placing 1 .2M shares with Seaside 88 LP; Enclave Capital served as placement agent (7/7) |
Advanced Life Sciences Holdings Inc. (OTC BB:ADLS) |
Private placement of units |
0.714U |
$3 |
Advanced Life Sciences offered up to 714,286 units at $4.20 each to raise $3M; Dawson James Securities acted as the exclusive placement agent (7/2) |
Advaxis Inc. (OTC BB:ADXS) |
Private placement of Series B preferred stock |
0.00075S |
$7.5 |
Advaxis raised $7.5M through the sale of 750 shares of Series B preferred stock priced at $10,000 per share; Optimus Capital Partners agreed to buy the shares over three years; Advaxis also issued an affiliate of Optimus a warrant to purchase up to 40.5M shares of common stock (7/21) |
Affymax Inc. (AFFY) |
Sale of auction rate securities |
N/A |
$5 |
Affymax generated $10.4M through the sale of auction rate securities held by UBS AG; $5.4M of the total was used to repay a loan from UBS, so remaining proceeds were $5M (7/21) |
ALDA Pharmaceuticals Corp. (Canada; CDNX:APH) |
Private placement of units |
3.25U |
-$0.291 |
ALDA did not proceed on the terms disclosed April 15 for a private placement due to prevailing market conditions; it was expected to raise $616,000, which was accounted for in the April chart; instead, it raised $325,000; the excess amount of $291 ,000 is being removed from the total (7/29) |
Bionovo Inc. (BNVI) |
Private placement of common stock |
N/A |
$15 |
Bionovo is receiving $15M through Aspire Capital Fund LLC, which will buy Bionovo's common stock over two years (7/8) |
Cell Therapeutics Inc. (CTIC) |
Private placement of preferred stock and warrants |
0.004S |
$4.06 |
Cell Therapeutics entered into an agreement to sell 4,060 shares of Series 6 preferred stock and warrants to buy an aggregate of 5.8M shares of common stock to an accredited investor (7/27) |
Gilead Sciences Inc. (GILD) |
Private placement of convertible senior notes due 2014 and 2016 |
N/A |
$2,200 |
Gilead priced an offering of convertible senior notes to qualified institutional buyers and expects net proceeds of $2. 166B (7/27) |
International Stem Cell Corp. (OTC BB:ISCO) |
Investment |
N/A |
$10 |
International Stem Cell secured $10M from German investment fund ARG Vermo-gensverwaltung AG and independent European sources (7/23) |
MediciNova Inc. (MNOV) |
Sale of auction rate securities |
N/A |
$9.5 |
MediciNova netted $9.5M after repaying the ARS loan from UBS AG (7/8) |
Northwest Biotherapeutics Inc. (OTC BB:NWBO) |
Private placement of restricted common stock |
N/A |
$2.65 |
Northwest raised $2.65M from private investors and SDS Capital (7/8) |
Novelos Therapeutics Inc. (OTC BB:NVLT) |
Private placement of common stock and warrants |
21 .4S and W for 16.07S |
$1 .5 |
Novelos entered an agreement with institutional investors to sell 21 .4M shares of common stock and five-year warrants to purchase up to 16.07M shares at 7 cents per share (7/23) |
Omeros Corp. (OMER) |
Committed equity financing facility |
N/A |
(up to $40M) |
Omeros may sell up to $40M of its shares of common stock to investor Azimuth Opportunity Ltd. over 24 months (7/30) |
Oncothyreon Inc. (ONTY) |
Committed equity financing facility |
N/A |
(up to $20M) |
Oncothyreon secured a facility to sell up to $20M of its shares to Small Cap Biotech Value Ltd. over a 24-month period (7/8) |
Oragenics Inc. (AMEX:ONI) |
Private placement of common stock |
5S |
$2 |
Oragenics raised $2M through the placement of 5M shares with the Koski Family Limited Partnership at a price of 40 cents per share (7/8) |
PharmAthene Inc. (AMEX:PIP) |
Registered direct offering |
2.79S and 1 .32W |
$3.9 |
PharmAthene is raising $3.9M by selling 2.79M shares at $1 .40 each along with 1 .32M six-year warrants with an exercise price of $1 .63 each; Roth Capital Partners served as the sole placement agent (7/21) |
StemCells Inc. (STEM) |
Private placement of common stock |
7S |
$6. 1 |
StemCells raised $6. 1M by selling the shares to Seaside 88 LP at $0.865 per share, a 12.6% discount; Seaside has agreed to purchase an additional 5M shares 12 weeks after the initial closing (7/1) |
Sunesis Pharmaceuticals Inc. (SNSS) |
Private placement of stock |
103.6S |
$28.5 |
Sunesis raised $28.5M pricing 103.6M shares at $0.275 cents each; investors were Bay City Capital, New Enterprise Associates, Alta Partners, Caxton Advantage Life Sciences Fund, Merlin Nexus, Nextech Venture, OpusPoint Partners, Venrock Associates and Vision Capital Advisors and members of Sunesis' management (7/2) |
XOMA Ltd. (XOMA) |
Committed equity financing facility |
N/A |
(up to $30M) |
XOMA can sell up to $30M of its registered common shares to Azimuth Opportunity Ltd. over a 12-month period (7/27) |
Notes: | ||||
